NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Palbociclib市場分析(2021年∼2025年)

Investigation Report on China's Palbociclib Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1006921
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Palbociclib市場分析(2021年∼2025年) Investigation Report on China's Palbociclib Market 2021-2025
出版日期: 2021年05月21日內容資訊: 英文 50 Pages
簡介

Palbociclib,是Pfizer在世界首次發售的週期蛋白依賴型激酶抑制劑(CDK4/6抑制劑)。Palbociclib,由於阻礙週期蛋白依賴型激酶,恢復細胞週期的控制,阻止癌細胞的增生。Palbociclib,主要用於進展乳癌的治療。2018年,Pfziner的Palbociclib(IBRANCE)進入中國市場。中國的Palbociclib市場上,至2020年Pfizer成為國內唯一的製藥企業。

中國市場進入後,Palbociclib的銷售量,從2018年的29萬8,630人民幣,2019年劇增到2,201萬人民幣。可是,2020年的銷售量為1,318萬人民幣減少了40.12%。這是起因於新型冠狀病毒感染疾病(COVID-19)的發生,影響醫院的營運。從2018年到2020年的Palbociclib的年複合成長率記錄了564.36%。

本報告提供中國的Palbociclib市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售額數,價格趨勢,市場預測,市場成長要素,市場機會,課題等資料彙整。

目錄

第1章 Palbociclib概要

  • Palbociclib的適應症
  • 中國的Palbociclib的開發
  • 中國的Palbociclib的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)的銷售額的影響

第2章 中國的Palbociclib的銷售趨勢(2018年∼2020年)

  • Palbociclib的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Palbociclib的銷售額數
    • 銷售額數:全體
    • 銷售額數:各地區
  • Palbociclib的銷售趨勢:各劑型
    • 膠囊
    • 其他劑型

第3章 中國的主要Palbociclib製造企業(2018年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售額數
  • Pfizer Europe MA EEIG
    • 企業簡介
    • Ibrance/IBRANCE(Palbociclib)的中國國內的銷售額

第4章 中國的Palbociclib的價格(2018年∼2020年)

  • GPfizer Europe MA EEIG(Ibrance/IBRANCE)

第5章 中國的Palbociclib市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105489

Palbociclib is the world's first selective inhibitor of CDK 4/6 launched by Pfizer. By inhibiting CDK 4/6, Palbociclib restores cell cycle control, thereby blocking tumor cell proliferation. Palbociclib is mainly used to treat advanced breast cancer. In 2018, Pfizer's Palbociclib, IBRANCE entered the Chinese market. By 2020, Pfizer Europe MA EEIG is the only manufacturer in the Chinese Palbociclib market.

According to CRI's market research, after Palbociclib went on the market in China, the sales increased rapidly from CNY298,630 in 2018 to CNY 22.01million in 2019. In 2020, the sales revenue was CNY13.18 million, which decreased 40.12% compared to that in 2019. The main reason is that the COVID-19 epidemic has impacted the overall hospitals' operation. The CAGR of Palbociclib from 2018 to 2020 is 564.36%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Palbociclib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase as the market expands. At the end of 2020, Pfizer applied for a new indication for Palbociclib in China. If the new indication is approved, the sales of Palbociclib will increase in the following years. On the other hand, Pfizer announced at the beginning of 2021 that it would reduce the price for Palbociclib by about 54%. Therefore, sales volume in 2021 is expected to increase, which will lead to revenue growth. At the same time, with the emergence of new CDK4/6 inhibitors and generic drugs in the Chinese market, the price of Palbociclib may continue to fall. The price reduction will make Palbociclib more affordable for patients, thus further opening up the market.

Topics Covered:

  • The impact of COVID-19 on China's Palbociclib market
  • Sales value of China's Palbociclib 2016-2020
  • Competitive landscape of China's Palbociclib market
  • Prices of Palbociclib in China
  • Prices of Palbociclib in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Palbociclib market
  • Prospect of China's Palbociclib market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Palbociclib

  • 1.1 Indications for Palbociclib
  • 1.2 Development of Palbociclib in China
  • 1.3 Governmental Approval of Palbociclib in China
  • 1.4 The Impact of COVID-19 on Palbociclib sales in China

2 Sales of Palbociclib in China, 2018-2020

  • 2.1 Sales Value of Palbociclib
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Palbociclib
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Palbociclib by Dosage Form in China, 2018-2020
    • 2.3.1 Capsule
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Palbociclib Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Palbociclib Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Pfizer Europe MA EEIG
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of IBRANCE (Pfizer's Palbociclib) in China

4 Prices of Palbociclib for Different Manufacturers in China, 2020-2021

  • 4.1 Pfizer Europe MA EEIG (IBRANCE)

5 Prospect of Chinese Palbociclib drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Palbociclib Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Palbociclib Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Palbociclib Capsule Registration in China
  • Chart Sales Value of Palbociclib Capsule over the World
  • Chart Sales Value of Palbociclib Capsule in China, 2018-2020
  • Chart Sales Value of Palbociclib Capsule in China by Regions, 2018-2020
  • Chart Sales Volume of Palbociclib Capsule in China, 2018-2020
  • Chart Sales Volume of Palbociclib Capsule in China by Regions, 2018-2020
  • Chart Market Share by Sales Value of Top Palbociclib Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of IBRANCE in China, 2018-2020
  • Chart Referential Prices of IBRANCE in China, 2020-2021
  • Chart Forecast on Sales Value of Palbociclib in China, 2021-2025
  • Chart Forecast on Sales Volume of Palbociclib in China, 2021-2025